TY - JOUR
T1 - Effectiveness of seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom
T2 - 2014/15 end of season results
AU - Pebody, Richard
AU - Warburton, Fiona
AU - Andrews, Nicholas
AU - Ellis, Joanna
AU - Von Wissmann, B.
AU - Robertson, C.
AU - Yonova, I.
AU - Cottrell, S.
AU - Gallagher, N.
AU - Green, Helen
AU - Thompson, Catherine
AU - Galiano, Monica
AU - Marques, D.
AU - Gunson, R.
AU - Reynolds, A.
AU - Moore, C.
AU - Mullett, D.
AU - Pathirannehelage, S.
AU - Donati, M.
AU - Johnston, J.
AU - De Lusignan, S.
AU - McMenamin, J.
AU - Zambon, Maria
N1 - Publisher Copyright:
© 2015, European Centre for Disease Prevention and Control (ECDC). All rights reserved.
PY - 2015/9/10
Y1 - 2015/9/10
N2 - The 2014/15 influenza season in the United Kingdom (UK) was characterised by circulation of predominantly antigenically and genetically drifted influenza A(H3N2) and B viruses. A universal paediatric influenza vaccination programme using a quadrivalent live attenuated influenza vaccine (LAIV) has recently been introduced in the UK. This study aims to measure the end-of-season influenza vaccine effectiveness (VE), including for LAIV, using the test negative case–control design. The overall adjusted VE against all influenza was 34.3% (95% confidence interval (CI) 17.8 to 47.5); for A(H3N2) 29.3% (95% CI: 8.6 to 45.3) and for B 46.3% (95% CI: 13.9 to 66.5). For those aged under 18 years, influenza A(H3N2) LAIV VE was 35% (95% CI: −29.9 to 67.5), whereas for influenza B the LAIV VE was 100% (95% CI:17.0 to 100.0). Although the VE against influenza A(H3N2) infection was low, there was still evidence of significant protection, together with moderate, significant protection against drifted circulating influenza B viruses. LAIV provided non-significant positive protection against influenza A, with significant protection against B. Further work to assess the population impact of the vaccine programme across the UK is underway.
AB - The 2014/15 influenza season in the United Kingdom (UK) was characterised by circulation of predominantly antigenically and genetically drifted influenza A(H3N2) and B viruses. A universal paediatric influenza vaccination programme using a quadrivalent live attenuated influenza vaccine (LAIV) has recently been introduced in the UK. This study aims to measure the end-of-season influenza vaccine effectiveness (VE), including for LAIV, using the test negative case–control design. The overall adjusted VE against all influenza was 34.3% (95% confidence interval (CI) 17.8 to 47.5); for A(H3N2) 29.3% (95% CI: 8.6 to 45.3) and for B 46.3% (95% CI: 13.9 to 66.5). For those aged under 18 years, influenza A(H3N2) LAIV VE was 35% (95% CI: −29.9 to 67.5), whereas for influenza B the LAIV VE was 100% (95% CI:17.0 to 100.0). Although the VE against influenza A(H3N2) infection was low, there was still evidence of significant protection, together with moderate, significant protection against drifted circulating influenza B viruses. LAIV provided non-significant positive protection against influenza A, with significant protection against B. Further work to assess the population impact of the vaccine programme across the UK is underway.
UR - http://www.scopus.com/inward/record.url?scp=84965093931&partnerID=8YFLogxK
U2 - 10.2807/1560-7917.ES.2015.20.36.30013
DO - 10.2807/1560-7917.ES.2015.20.36.30013
M3 - Article
C2 - 26535911
AN - SCOPUS:84965093931
SN - 1025-496X
VL - 20
JO - Eurosurveillance
JF - Eurosurveillance
IS - 36
ER -
